South African lab technician Nozipho Mlotshwa was waiting for the test results for a potential HIV vaccine, which has eluded ...
Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, ...
By paralyzing frontline response efforts led by community groups, the US decision to freeze funding is weakening health systems across the Global South. The freeze not only jeopardizes precious gains ...
The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...
The U.N.'s Angeli Achrekar reports that many clinics have closed, despite exemptions in the policy. She fears mortality will ...
An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...
Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the ...
Supercomputer simulations have revealed how changes in the shape of the HIV-1 capsid protein may help the virus squeeze its ...
Understand how drug use increases HIV risk and learn about prevention strategies that save lives. Medical experts explain ...
Human immunodeficiency virus (HIV) treatment has gotten so good that people can take a pill once a day to achieve viral ...
Doxycycline post-exposure significantly reduced the incidence of sexually transmitted infections among individuals using HIV pre-exposure prophylaxis.